Curriculum Vitae

William David Summers, M.D.
Alabama Clinical Therapeutics, LLC
52 Medical Park East Drive, Suite 203
Birmingham, Alabama 35235

Telephone: (205) 833-2228
Fax: (205) 833-6225

Additional Offices:

Private Practice
52 Medical Park East Drive, Suite 215
Birmingham, Alabama 35235

Education:

1986 – 1989	OB-GYN, Residency University of Tennessee – Regional Medical Center Memphis, TN
1985 – 1986	OB-GYN, Internship University of Tennessee – Regional Medical Center Memphis, TN
1981 – 1985	Medical Degree University of Tennessee College of Medicine Memphis, TN
1977 – 1981	Bachelor of Science University of Memphis Memphis, TN

Work Experience:

2006-Present	Investigator Alabama Clinical Therapeutics Birmingham, Alabama
2006-Present	Private Practice 52 Medical Park East Drive, Suite 207 Birmingham, Alabama 35235

Work Experience (continued):

1989-2006	Physician Eastern Obstetrics & Gynecology, P.C. Birmingham, Alabama

Hospital Affiliations:

Medical Center East

Certifications and Licenses:

1989	M.D. – Alabama # 14623
1989	M.D. – Tennessee # 17261
1991	Board Certified American College of Obstetrics and Gynecology

Research Experience:

1."Ninety Days of Treatment with XXX vs. XXX to Improve Anemia Before Surgical Management to Uterine Leiomyomas"

2."An Open-Label, Randomized, Parallel Group, Comparative, Multicenter, Safety and Efficacy Study of XXX vs. XXX"

3."A Randomized, Double-Blind, Active and Placebo Controlled Study of the Analgesic Efficacy and Safety of Repeated Dosing of Two Dose Levels of XXX Relative to XXX and Placebo in Patients with Acute Post-Operative Pain after Abdominal Surgery"

4."A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of XXX for Treatment of Pain in Post-Operative Adult Patients"

5."A RANDOMIZED, DOUBLE-BLIND, ACTIVE-AND PLACEBO-CONTROLLED STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF REPEATED DOSING OF TWO DOSE LEVELS OF XXX TO PARENTERAL XXX AND PLACEBO IN PATIENTS WITH ACUTE POST-OPERATIVE PAIN AFTER ABDOMINAL OR PELVIC SURGERY"

6."A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of XXX for Treatment of Pain in Post-Operative Adult Patients, Phase B"

7."A Multicenter, Open-Label, Dose-Titration, Safety And Efficacy One Year Extension Study Of The Selective XXX In Pre-Menopausal Women With Symptomatic Leiomyomata Who Have Previously Completed Study"

8."A Double-Blind, Randomized, Randomized, Placebo-and-Active-Controlled Efficacy and Safety Study of XXX combinations for Prevention of Endometrial Hyperplasia and Prevention of Osteoporosis in Postmenopausal Women"

Research Experience (continued):

9."A Long-term, Open Label, Multicenter Study to Evaluate the Safety of XXX Oral Dose of a New Modified-Release III Three Times Daily for up to 5 Days During the Menstrual Cycle in Women with Heavy Menstrual Bleeding Associated with Menorrhagia"

10. A Multi-Center, Placebo Controlled, Safety and Efficacy Study of the Selective Progesterone Receptor Modulator XXX in Anemic, Pre-Menopausal Women with Symptomatic Uterine Fibroids Requiring Hysterectomy"

11. A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Repeated-Dose Study of the Analgesic Efficacy and Safety of XXX Versus Placebo for the Treatment of Postoperative Pain After Abdominal Laparoscopic Surgery

12. "A Phase III, Three-arm, Parallel Design, Placebo-controlled, Randomized, Double-blind, Multicenter Study Evaluating the Safety and Efficacy of XXX in the Treatment of Premenopausal Women with Symptomatic Uterine Fibroids"

13. A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of XXX Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women

14. A DOUBLE-BLIND, RANDOMIZED, PLACEBO-AND ACTIVE-CONTROLLED EFFICACY AND SAFETY STUDY OF THE EFFECTS OF XXX COMBINATIONS ON ENDOMETRIAL HYPERPLASIA AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

15. A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY AND EFFICACY OF XXX FOR THE TREATMENT OF VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE

16. Multi-center, open-label, uncontrolled study to investigate the efficacy and safety of the transdermal contraceptive patch containing XXX in a 21-day regimen for 13 cycles in 1650 healthy female subjects

17. A twenty-four week, randomized, double-blind, placebo-controlled, safety and efficacy trial of XXXXXX, with up-titration, 100 milligrams administered orally once daily in naturally postmenopausal women with hypoactive sexual desire disorder in North America

18. A Twenty-Eight Week, Open-Label, Safety, Extension Trial of XXXXXX 100 Milligrams Daily in Premenopausal and Naturally Postmenopausal Women with Hypoactive Sexual Desire Disorder in North America

19. An Open Label Study to Evaluate the Contraceptive Efficacy and Safety of XXXXXX Transdermal Delivery System

20. A Multicenter, Open-Label, Randomized Study of the Contraceptive Efficacy and Safety of xxx Compared to xxx

Research Experience (continued):

21. Evaluate the Efficacy and Safety of XXX in Subjects with Moderate to Severe Endometriosis Associated Pain

22. A Randomized, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of XXX in Women with Anemia Associated with Uterine Leiomyomas

23. Extension Study to Evaluate the Long-Term Safety and Efficacy of XXX in Subjects with Moderate to Severe Endometriosis-Associated Pain

24. A Phase 2b Study to Evaluate the Safety and Efficacy of XXX in Premenopausal Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids

25. A Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability and Pharmacokinetics of XXX During 13 Cycles

26. A single-arm, open-label, multicenter Phase 3 study of the contraceptive efficacy and tolerability of the XXX transdermal contraceptive delivery system (TCDS)

27. A Phase 2, Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg XXX Administered Orally in the Treatment of Premenopausal Women with Confirmed Symptomatic Uterine Fibroids

28. A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination with XXX for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women

29. A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with XXX in Subjects with Moderate to Severe Endometriosis-Associated Pain

30. Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids

31. A Multicenter, Randomized, Double-Blind, Vehicle Controlled Study Evaluating the Therapeutic Equivalence and Safety of GDC-229 (Investigational Metronidazole 0.75% Vaginal Gel) and Metronidazole 0.75% Vaginal Gel in the Treatment of Bacterial Vaginosis

32. A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Clinical Study of XXX for the 26-Week Continuous Treatment of Abnormal Uterine Bleeding in Women with Uterine Fibroids

33. A Phase 3b Study to Evaluate the Long-Term Safety and Efficacy of XXX in Combination with XXX for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Postmenopausal Women



William David Summers, M.D.

08-2020

Date